[96a5a0]: / output / allTrials / identified / NCT00003873_identified.json

Download this file

662 lines (662 with data), 30.6 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
{
"info": {
"nct_id": "NCT00003873",
"official_title": "Phase III Trial Comparing a 28 Day Schedule of Daily Oral 5-FU Plus Eniluracil to Protracted Intravenous Infusion in Previously Untreated Patients With Advanced Colorectal Cancer",
"inclusion_criteria": "* Patients with measurable or nonmeasurable histologically confirmed adenocarcinoma of the colon and rectum are eligible provided patient has metastatic, recurrent or residual disease, and tumor is beyond hope of surgical eradication; all pre-study scans documenting disease must be done =< 4 weeks prior to randomization\n\n * Measurable tumor is defined as a known mass that can be clearly measured in two dimensions by physical examination, CT scan, radionuclide liver scan, or on chest x-ray by a ruler or calipers; the largest diameter of the lesion must measure >= 2 cm by at least one method of evaluation\n* Patients must have had no prior therapy for advanced disease\n* Patients may have had prior adjuvant treatment with 5-FU provided that the last dose was received > 12 months prior to entering the study; no prior chemotherapy other than adjuvant 5-FU is allowed\n* Patients with prior radiotherapy are acceptable, but patients should have measurable or nonmeasurable disease outside the radiation port and/or progressive disease within the previously radiated volume; in addition, it must be at least 2 weeks since administration of radiation therapy and all signs of toxicity must have abated\n* Bilirubin =< 1.5 x upper limit of normal (ULN)\n* SGOT =< 3 x ULN\n* Because Eniluracil changes the metabolism of 5-FU such that it is excreted primarily by the kidneys, an estimated creatinine clearance calculated using the Cockcroft and Gault formula must be obtained in patients with a serum creatinine > institutional normal limits; the estimated creatinine clearance must be >= 50 ml/min prior to starting treatment with Eniluracil/5-FU; if not, a measured creatinine clearance must be done (using a 24 hour urine collection); the measured creatinine clearance must be > 50 ml/min for the patient to be eligible\n* Absolute neutrophil count >= 2000 mm³\n* Platelet count >= 100,000 mm³\n* ECOG performance status 0-2\n* No evidence of significant active infection (e.g., pneumonia, peritonitis, wound abscess, etc.) at time of study entry\n* No evidence of serious intercurrent illness such as uncontrolled diabetes mellitus, hypothyroidism, malabsorption syndrome or heart failure\n* No prior neoplastic diseases (within 5 years) aside from the current malignancy or curatively resected melanoma, skin cancer or cervical carcinoma in situ\n* No treatment with folinic acid, interferon, flucytosine or topical 5-FU within the previous 14 days\n* Not pregnant or lactating; pregnant and lactating women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage\n* Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patients with measurable or nonmeasurable histologically confirmed adenocarcinoma of the colon and rectum are eligible provided patient has metastatic, recurrent or residual disease, and tumor is beyond hope of surgical eradication; all pre-study scans documenting disease must be done =< 4 weeks prior to randomization",
"criterions": [
{
"exact_snippets": "measurable or nonmeasurable histologically confirmed adenocarcinoma of the colon and rectum",
"criterion": "adenocarcinoma of the colon and rectum",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "histologically confirmed"
},
{
"requirement_type": "measurability",
"expected_value": [
"measurable",
"nonmeasurable"
]
}
]
},
{
"exact_snippets": "metastatic, recurrent or residual disease",
"criterion": "disease status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"metastatic",
"recurrent",
"residual"
]
}
]
},
{
"exact_snippets": "tumor is beyond hope of surgical eradication",
"criterion": "tumor surgical eradication potential",
"requirements": [
{
"requirement_type": "eradication potential",
"expected_value": false
}
]
},
{
"exact_snippets": "all pre-study scans documenting disease must be done =< 4 weeks prior to randomization",
"criterion": "pre-study scans timing",
"requirements": [
{
"requirement_type": "timing",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Measurable tumor is defined as a known mass that can be clearly measured in two dimensions by physical examination, CT scan, radionuclide liver scan, or on chest x-ray by a ruler or calipers; the largest diameter of the lesion must measure >= 2 cm by at least one method of evaluation",
"criterions": [
{
"exact_snippets": "Measurable tumor is defined as a known mass that can be clearly measured in two dimensions",
"criterion": "measurable tumor",
"requirements": [
{
"requirement_type": "definition",
"expected_value": "a known mass that can be clearly measured in two dimensions"
}
]
},
{
"exact_snippets": "by physical examination, CT scan, radionuclide liver scan, or on chest x-ray",
"criterion": "measurement method",
"requirements": [
{
"requirement_type": "methods",
"expected_value": [
"physical examination",
"CT scan",
"radionuclide liver scan",
"chest x-ray"
]
}
]
},
{
"exact_snippets": "the largest diameter of the lesion must measure >= 2 cm",
"criterion": "lesion size",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "cm"
}
}
]
}
]
},
{
"line": "* Patients must have had no prior therapy for advanced disease",
"criterions": [
{
"exact_snippets": "no prior therapy for advanced disease",
"criterion": "prior therapy for advanced disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients may have had prior adjuvant treatment with 5-FU provided that the last dose was received > 12 months prior to entering the study; no prior chemotherapy other than adjuvant 5-FU is allowed",
"criterions": [
{
"exact_snippets": "Patients may have had prior adjuvant treatment with 5-FU",
"criterion": "prior adjuvant treatment with 5-FU",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "the last dose was received > 12 months prior to entering the study",
"criterion": "time since last dose of 5-FU",
"requirements": [
{
"requirement_type": "time since last dose",
"expected_value": {
"operator": ">",
"value": 12,
"unit": "months"
}
}
]
},
{
"exact_snippets": "no prior chemotherapy other than adjuvant 5-FU is allowed",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients with prior radiotherapy are acceptable, but patients should have measurable or nonmeasurable disease outside the radiation port and/or progressive disease within the previously radiated volume; in addition, it must be at least 2 weeks since administration of radiation therapy and all signs of toxicity must have abated",
"criterions": [
{
"exact_snippets": "prior radiotherapy",
"criterion": "prior radiotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "measurable or nonmeasurable disease outside the radiation port",
"criterion": "disease outside the radiation port",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "progressive disease within the previously radiated volume",
"criterion": "progressive disease within the previously radiated volume",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "at least 2 weeks since administration of radiation therapy",
"criterion": "time since radiation therapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "all signs of toxicity must have abated",
"criterion": "signs of toxicity",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Bilirubin =< 1.5 x upper limit of normal (ULN)",
"criterions": [
{
"exact_snippets": "Bilirubin =< 1.5 x upper limit of normal (ULN)",
"criterion": "bilirubin level",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 1.5,
"unit": "x ULN"
}
]
}
}
]
}
]
},
{
"line": "* SGOT =< 3 x ULN",
"criterions": [
{
"exact_snippets": "SGOT =< 3 x ULN",
"criterion": "SGOT",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 3,
"unit": "x ULN"
}
}
]
}
]
},
{
"line": "* Because Eniluracil changes the metabolism of 5-FU such that it is excreted primarily by the kidneys, an estimated creatinine clearance calculated using the Cockcroft and Gault formula must be obtained in patients with a serum creatinine > institutional normal limits; the estimated creatinine clearance must be >= 50 ml/min prior to starting treatment with Eniluracil/5-FU; if not, a measured creatinine clearance must be done (using a 24 hour urine collection); the measured creatinine clearance must be > 50 ml/min for the patient to be eligible",
"criterions": [
{
"exact_snippets": "serum creatinine > institutional normal limits",
"criterion": "serum creatinine",
"requirements": [
{
"requirement_type": "comparison",
"expected_value": {
"operator": ">",
"value": 0,
"unit": "institutional normal limits"
}
}
]
},
{
"exact_snippets": "estimated creatinine clearance ... >= 50 ml/min",
"criterion": "estimated creatinine clearance",
"requirements": [
{
"requirement_type": "comparison",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "ml/min"
}
}
]
},
{
"exact_snippets": "measured creatinine clearance ... > 50 ml/min",
"criterion": "measured creatinine clearance",
"requirements": [
{
"requirement_type": "comparison",
"expected_value": {
"operator": ">",
"value": 50,
"unit": "ml/min"
}
}
]
}
]
},
{
"line": "* Absolute neutrophil count >= 2000 mm³",
"criterions": [
{
"exact_snippets": "Absolute neutrophil count >= 2000 mm³",
"criterion": "absolute neutrophil count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 2000,
"unit": "mm³"
}
}
]
}
]
},
{
"line": "* Platelet count >= 100,000 mm³",
"criterions": [
{
"exact_snippets": "Platelet count >= 100,000 mm³",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 100000,
"unit": "mm³"
}
}
]
}
]
},
{
"line": "* ECOG performance status 0-2",
"criterions": [
{
"exact_snippets": "ECOG performance status 0-2",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* No evidence of significant active infection (e.g., pneumonia, peritonitis, wound abscess, etc.) at time of study entry",
"criterions": [
{
"exact_snippets": "No evidence of significant active infection",
"criterion": "active infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "pneumonia",
"criterion": "pneumonia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "peritonitis",
"criterion": "peritonitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "wound abscess",
"criterion": "wound abscess",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* No evidence of serious intercurrent illness such as uncontrolled diabetes mellitus, hypothyroidism, malabsorption syndrome or heart failure",
"criterions": [
{
"exact_snippets": "No evidence of serious intercurrent illness such as uncontrolled diabetes mellitus",
"criterion": "diabetes mellitus",
"requirements": [
{
"requirement_type": "control",
"expected_value": true
}
]
},
{
"exact_snippets": "No evidence of serious intercurrent illness such as ... hypothyroidism",
"criterion": "hypothyroidism",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No evidence of serious intercurrent illness such as ... malabsorption syndrome",
"criterion": "malabsorption syndrome",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No evidence of serious intercurrent illness such as ... heart failure",
"criterion": "heart failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* No prior neoplastic diseases (within 5 years) aside from the current malignancy or curatively resected melanoma, skin cancer or cervical carcinoma in situ",
"criterions": [
{
"exact_snippets": "No prior neoplastic diseases (within 5 years)",
"criterion": "prior neoplastic diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "aside from the current malignancy",
"criterion": "current malignancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "curatively resected melanoma",
"criterion": "curatively resected melanoma",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "curatively resected ... skin cancer",
"criterion": "curatively resected skin cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "curatively resected ... cervical carcinoma in situ",
"criterion": "curatively resected cervical carcinoma in situ",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* No treatment with folinic acid, interferon, flucytosine or topical 5-FU within the previous 14 days",
"criterions": [
{
"exact_snippets": "No treatment with folinic acid ... within the previous 14 days",
"criterion": "folinic acid treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No treatment with ... interferon ... within the previous 14 days",
"criterion": "interferon treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No treatment with ... flucytosine ... within the previous 14 days",
"criterion": "flucytosine treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No treatment with ... topical 5-FU within the previous 14 days",
"criterion": "topical 5-FU treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Not pregnant or lactating; pregnant and lactating women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage",
"criterions": [
{
"exact_snippets": "Not pregnant",
"criterion": "pregnancy status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
},
{
"exact_snippets": "Not ... lactating",
"criterion": "lactation status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
}
]
},
{
"line": "* Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception",
"criterions": [
{
"exact_snippets": "Women of childbearing potential",
"criterion": "childbearing potential",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "sexually active males",
"criterion": "sexual activity",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}